Cell viability (IC50 values) of GA derivatives in ovarian cancer cells.
| Compounds | IC50a (μM) | Compounds | IC50a (μM) | ||
|---|---|---|---|---|---|
| SKOV3 | OVCAR3 | SKOV3 | OVCAR3 | ||
| 4a | 78.0 ± 0.8 | 71.6 ± 2.4 | 7a | 58.7 ± 1.8 | 53.0 ± 2.0 |
| 4b | 42.1 ± 1.2 | 69.9 ± 1.8 | 7b | 59.0 ± 1.0 | 53.2 ± 2.2 |
| 4c | 59.9 ± 1.7 | 68.4 ± 1.2 | 7c | 27.9 ± 1.4 | 33.9 ± 1.1 |
| 4d | >100 | 84.6 ± 2.0 | 7d | >100 | 56.5 ± 2.8 |
| 4e | 71.3 ± 1.1 | >100 | 7e | 45.4 ± 2.1 | 54.4 ± 1.0 |
| 4f | 84.9 ± 1.7 | 78.0 ± 2.2 | 7f | 58.9 ± 1.1 | 48.2 ± 2.0 |
| 4g | 74.3 ± 1.9 | 63.1 ± 2.6 | 7g | 49.4 ± 3.0 | 44.0 ± 1.8 |
| 4h | >100 | >100 | 7h | 56.7 ± 1.9 | 45.0 ± 1.9 |
| 4i | 95.0 ± 2.4 | 60.7 ± 2.0 | 7i | >100 | 48.2 ± 2.4 |
| Paclitaxel | 0.43 ± 0.03 | 0.38 ± 0.04 | GA, 1 | 98.5 ± 1.6 | 72.4 ± 2.2 |
a
IC50: concentration that inhibits 50% of cell growth. The values are presented as the mean ± SD (standard error of the mean) from three separated experiments.